Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
Active, not recruiting · Phase 2 · NCT03824483
Conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL)
At a glance
- Research payments reported, 2025
- $1.4M
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 230
About the trial
- Sponsor
- Memorial Sloan Kettering Cancer Center (with Roche-Genentech, Massachusetts General Hospital, BeOne Medicines)
- Tested
- Zanubrutinib (drug), Obinutuzumab (drug), Venetoclax (drug)
- Dates
- Started 2019-02-22; completion 2027-02
- Results posted
- Not yet
The purpose of this study is to determine the rate of minimum residual disease (MRD) negative response (i.e. the rate of no evidence of disease) of the study drugs, zanubrutinib, obinutuzumab, and venetoclax, given in combination as a treatment for CLL and/or SLL.
From ClinicalTrials.gov, last updated 2026-09-03. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beone Medicines USA, Inc. reported $1.4M in research payments for this study in 2025 (3 payments).
Products named: Brukinsa
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Memorial Sloan Kettering Cancer Center $1.4M
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.